About Us

Avista Pharma Solutions is a contract testing, development and manufacturing organization encompassing over 200,000 square feet of laboratory and manufacturing space across three locations (Agawam, MA – Durham, NC – Longmont, CO), providing pharmaceutical, animal health and medical device clients with a broad suite of scientifically-differentiated services ranging from early drug development and drug product manufacturing to stand-alone analytical and microbiology testing support.


Members of the Avista Pharma Executive Team

Patrick Walsh, CEO & Member of the Board of Directors

Patrick is an experienced CEO whose leadership teams are recognized for their stellar performances and high growth achievements. He has extensive experience directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation, manufacturing and analytical contract development organizations. Patrick has served as Chairman, Non-Executive Chairman and a company Director in twelve (12) organizations as well as an Executive Advisor to private equity and venture capital firms.  At Avista Pharma Solutions (Avista Pharma), Patrick also serves as a member of the Board of Directors.


Prior to Avista Pharma, Patrick was CEO of AAIPharma Services, where he led the successful growth strategy culminating in the sale of the company for a 4.6 times return on invested capital.


Prior executive roles include CEO roles in several life science companies and President & COO of Gensia-Sicor. He started his career as a sales representative for Invenex Labs and LyphoMed.


He holds a degree in General Studies and resides in North Carolina with his wife and 3 children.


Eric Setzer, CFO

Eric Setzer is a finance and operations executive with over twenty years of experience in various roles within growing technology and life science companies. Prior to joining Avista Pharma Solutions, he served as the Executive Director of Finance at INC Research, a publicly traded clinical research organization in Raleigh, NC. Previously, Eric served as CFO of Expression Analysis, a genomics service provider located in Research Triangle Park, North Carolina, which was sold to Quintiles in 2012. Eric was also CFO of three separate venture capital-funded companies in the health care technology sector, and he was the Controller of TriPath Imaging, a publicly traded cervical cytology screening company. Eric began his career in public accounting, working for Price Waterhouse in Rochester, New York, and the Entrepreneurial Services Group of Ernst & Young in Raleigh, North Carolina.

Eric received his MBA from Duke University, has an undergraduate degree in Accounting and Economics from Oswego State University and is a licensed Certified Public Accountant.


Bill Bissinger, CIO

Bill Bissinger is an Information Technology executive with over 30 years of experience in business Information Technology and leadership across a broad range of industries and business models, including 20 years in the pharmaceutical industry. Bill also has experience in petroleum, packaging, custom films, aerospace and defense, and beverage industries in manufacturing, contract services, wholesale, retail, and distribution. Prior to joining Avista Pharma Solutions, he served as CIO for AAIPharma Services and as CIO for Banner Pharmacaps, Inc. a global gelatin-based drug delivery and specialty pharmaceutical company.
Bill has served on the Information Systems and Master of Computer Science Information System (MS CSIS) Advisory Board for UNCW andon the Advisory Board for Information Systems and Supply Chain Management at the Bryan School of Business and Economics at UNCG and is active in IT industry organizations. Bill holds a B.A. in Business Administration with an additional concentration in Physics from Queens University in Charlotte, NC as well as an Associate degree in Information Technology from AB Technical College in Asheville, NC.


Members of the Avista Pharma Leadership Team

Ken Domagalski, VP of Manufacturing

Ken has over 30 years in the pharmaceutical industry of which 20 years were with Teva Parenteral Medicines. Ken has served in various executive roles including Vice President of Quality, Vice President of Operations, and Vice President of Process Engineering & Validation. He has led global organizations with hands-on experience including validation of systems, equipment, cleaning, product and processes in support of facility startups and new product introductions.


During his tenure at Teva Parenteral Medicines, Ken led and/or provided significant direction in the build-out of a dedicated high potency facility, a facility for sterile suspensions as well as a facility for the manufacture of sterile emulsions. Ken also led automation efforts for the quality support systems as part of the facility and system design and enhancements.


Ken has led numerous successful FDA, EMEA, MCA and other international cGMP inspections.


Ken holds a B.S. in Biology and Life Sciences from Niagara University.


Donald Harrigan, VP of Regulatory Affairs & Quality Assurance

Donald brings over 35 years of pharmaceutical, medical device and biotechnology experience. Don has served in various key roles including Vice President of Regulatory Affairs, Vice President of Quality and Vice President of Scientific Affairs. He is a subject matter expert in scientific affairs pertaining to the development of NDA, ANDA, 505(b)(2), BLA and 510(K) filings. His expertise also includes various quality-related functions including oversight of quality assurance and laboratory-related activities.


For the past 10 years, Don has been a consultant to the pharmaceutical industry, being responsible for direct oversight of product registrations and site inspections performed by FDA and other health authorities. During this period he worked internationally to provide guidance and leadership in quality and regulatory areas in the build-out of international API and Aseptic Sterile Manufacturing facilities.


Don’s prior roles include VP of Regulatory Affairs and Compliance for Gensia-Sicor and Director of Regulatory Compliance for LyphoMed, Inc.


Don holds a B.S. in Pharmacy, a B.S. in Pharmaceutical Chemistry and a M.S. in Chemical Engineering from the SUNY at Buffalo.


Joe Miller, VP of Process Chemistry and Manufacturing Services

Joe has worked in the chemical industry for more than 30 years, including Procter & Gamble, Ethyl Corporation, Henkel Research Corporation, and Exxon Chemical Company early in his career. The last 20+ years, however, have been spent in the pharmaceutical CDMO business. Since 1995, he has held senior leadership roles in Process Chemical R&D at Catalytica-DSM Pharmaceuticals, Pharmacore and Irix Pharmaceuticals-Patheon. Joe joined Avista Pharma Solutions in June, 2016 and is responsible for Process Chemistry and Manufacturing at both the Durham, NC and Longmont, CO sites.


Joe received his Ph.D. in 1982 from the University of California, Davis. He then worked as a post-doctoral research assistant with Professor Ei-ichi Negishi, 2010 Nobel Chemistry Laureate, at Purdue University for two years. He is the author of 30 chemical research publications, two review articles on organoaluminum chemistry, and 12 US Patents.


Rob Goshert, VP of Business Operations

Rob is a pharmaceutical industry veteran of 35 years with over 30 years of management experience. He has been instrumental in building teams, developing business plans and leading operations in global sales, marketing, project management, proposals, contracts, client services and manufacturing operations. Rob began his pharmaceutical career with Ciba-Geigy (now Novartis) before following his passion of guiding smaller companies to high-growth successes.


Rob’s experience includes influential positions at LyphoMed, Fujisawa, Gensia-Sicor and AAIPharma, all of which experienced explosive growth during his tenure.


Rob and his wife of 34 years are each graduates of Butler University in Indianapolis and are the proud parents of 2 young men.


Timothy Compton, VP of Business Development

Timothy is an industry professional with a successful track record in R&D, sales team management, business development and corporate marketing. Tim’s first 10 years of his career were in Research and Development (R&D) developing oncology diagnostics and advancing novel pain therapeutics with Atairgin Technologies and Kadmus Pharmaceuticals, respectively.  Following his successful tenure at the bench, Tim took on increasing roles of responsibility within Business Development at Baypoint Biosystems, Irvine Pharmaceutical Services and as Executive Director of Business Development at AAIPharma Services. He led the sales team at AAIPharma, which more than doubled annual sales and brought over 500 new clients to the company, and he led the company’s corporate marketing initiatives.


Tim holds a B.S. in Microbiology from Washington State University and is an active duty veteran of the U.S. Army.


External Members of the Board of Directors (Ampersand Capital Partners)

David J. Parker

Dave, who has more than 15 years of private equity experience, joined Ampersand in 1994. Dave’s board seats have included Bako, NOVEX, Signature Genomics and Roadrunner. Prior to joining Ampersand, Dave spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and an M.B.A. from Wharton.  For additional information, see Ampersand Capital Partners.


Herbert H. Hooper

Herb, who joined Ampersand in 2002, has more than twenty years of experience working with Healthcare companies – first as an entrepreneur at Ampersand portfolio company ACLARA Biosciences, and later as an Ampersand Managing Partner. His current and past board seats include ACLARA, Bako, Signature Genomics and Viracor-IBT Laboratories. He also serves on the College of Chemistry Advisory Board for the University of California, Berkeley. Herb holds a B.S. in Chemical Engineering from North Carolina State and a Ph.D. in Chemical Engineering from the University of California, Berkeley.  For additional information, see Ampersand Capital Partners.